Related Experiment Video

Updated: Nov 28, 2025

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
09:48

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

Published on: September 12, 2019

8.4K

Dostarlimab in the treatment of recurrent or primary advanced endometrial cancer

Lawrence Kasherman1, Soha Ahrari2, Stephanie Lheureux1

  • 1Division of Medical Oncology & Hematology, Bras Family Drug Development Program, Princess Margaret Cancer Centre, 610 University Avenue, Toronto, ON M5G 2M9, Canada.

Future Oncology (London, England)
|November 30, 2020
PubMed

Insights

Dostarlimab, a PD-1 inhibitor, shows promise for recurrent endometrial cancer (EC), especially in the microsatellite instability-hypermutated subtype. This review details its efficacy and safety in advanced EC patients.

Area of Science:

  • Oncology
  • Immunotherapy
  • Gynecologic Oncology

Background:

  • Immune checkpoint inhibitors (ICIs) show efficacy in various cancers but have modest utility in gynecologic malignancies.
  • Endometrial cancer (EC) research focuses on molecular subtypes, particularly microsatellite instability-hypermutated (MSI-H)/DNA mismatch repair-deficient (dMMR) for ICI response.
  • Dostarlimab, a PD-1 inhibitor, has preliminary data suggesting clinical activity and safety in recurrent EC.

Purpose of the Study:

  • To review existing data on the efficacy and safety of dostarlimab.
  • To focus on dostarlimab's use in recurrent or advanced-stage endometrial cancer.
  • To highlight its potential in specific EC molecular subtypes.

Main Methods:

  • Review of published clinical trial data.
  • Analysis of safety and efficacy endpoints for dostarlimab in EC.
  • Focus on patients with recurrent or advanced-stage disease.

Main Results:

  • Dostarlimab demonstrates preliminary clinical activity in recurrent EC.
  • The safety profile of dostarlimab appears acceptable in this patient population.
  • Activity is particularly noted in the MSI-H/dMMR EC subtype.

Conclusions:

  • Dostarlimab shows potential as a treatment option for recurrent or advanced-stage EC.
  • The MSI-H/dMMR subtype appears to be a predictive biomarker for response to dostarlimab.
  • Further investigation into dostarlimab's role in EC treatment is warranted.
Keywords:
PD-1 inhibitorTSR-042dostarlimabendometrial carcinomagynecologic/endometrialimmune checkpoint inhibitorimmunotherapy

More Related Videos

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.7K
Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.4K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.2K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.3K
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
662